Pharma in emerging economies: risks, concerns, and considerations
Emerging markets in BRIC nations are gaining traction and will be a key revenue driver for multinational pharma companies – but not without risk.
Archives for January 20, 2016
Mylan: GMP issues and production halt at Agila aseptic plant 'not material'
Mylan has stopped production at a sterile injectables plant after Polish regulators observed 29 major violations of GMP, an EU statement of non-compliance reveals.
Parexel acquires life sciences consulting firm Health Advances
Parexel has acquired a life sciences strategy consulting firm as it continues to build on its existing portfolio.
Novozymes says pharma won't drive growth and sets up albumin subsidiary
Novozymes has launched its albumin operations as a stand-alone subsidiary and reiterated that its pharma business is no longer a growth driver.
US NIAID awards $5m to researchers developing non-traditional therapeutics for bacterial infections
$5m in funding has been awarded to various research projects in order to help develop non-traditional therapeutics for bacterial infections.
Bioclinica buys Clinverse citing pharma demand for trial payment efficiency
Bioclinica has bought payment tech firm Clinverse continuing its acquisition-based growth strategy.
New Novozymes subsidiary Albumedix to develop its own drug pipeline says CEO
Novozymes’ new subsidiary Albumedix has announced its intention to develop biobetters and says the first candidate could be in Phase I trials by 2019.